A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy

This study is specifically looking for adult men aged 18 or older who have been diagnosed with a type of cALD that is currently getting worse, as seen on brain scans. You might be a good fit if a stem cell transplant (HSCT) isn't recommended for you, or if you prefer not to have one.

There are also some specific requirements based on your brain scan scores and your current physical and mental abilities. For example, your brain scan Loes score needs to be within a certain range. You should not have major problems with daily activities, though some issues like being in a wheelchair or bladder control problems are understood as part of the disease and won't stop you from joining.

However, you can't join if you've already had a stem cell transplant or certain gene therapies. People with known type 1 or type 2 diabetes, or allergies to similar medications, also can't take part. You also shouldn't be taking certain other medications or participating in another drug study at the same time.

Taking part in this study would involve regular visits to the study clinic where you'll have various check-ups and assessments. You will be given either the study drug, Leriglitazone, or a placebo, which you'll take as instructed. The medical team will closely monitor your health, perform tests, and ask you about any symptoms or side effects you might experience. They'll likely do brain scans and other neurological assessments to track the progress of your condition and see how the treatment is working. The exact number of visits and the total length of your participation will be explained by the study team, but clinical trials typically involve follow-up over several months or even longer.